TheraRadar
Clinical-Stage Companies / Mabwell (Shanghai) Bioscience

Mabwell (Shanghai) Bioscience

Pre-Approval PRO BETA
34
Total Trials
8
Phase 3
14
Phase 2
18
Recruiting
333
Score

Pipeline by Phase

Phase 3
8
Phase 2
14
Phase 1
22

Therapeutic Focus

Urothelial Carcinoma Solid Tumors Asthma COPD Atopic Dermatitis

Clinical Trials (34)

NCT06196736 Phase 3 RECRUITING

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Started: 12/29/2023

NCT06804590 Phase 3 RECRUITING

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

Started: 11/16/2024

NCT06692166 Phase 3 RECRUITING

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Started: 9/10/2024

NCT06592326 Phase 3 RECRUITING

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Started: 8/22/2024

NCT05215977 Phase 3 COMPLETED

Efficacy and Safety of MW031 in PMO Subjects

Started: 12/27/2019

NCT04812509 Phase 3 COMPLETED

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Started: 3/20/2020

NCT07556848 Phase 3 NOT YET RECRUITING

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Started: 5/1/2026

NCT07314723 Phase 2 RECRUITING

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Started: 8/1/2025

NCT07292714 Phase 2 RECRUITING

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Started: 7/15/2025

NCT06823427 Phase 2 RECRUITING

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Started: 1/17/2025

NCT06492005 Phase 2 RECRUITING

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Started: 7/26/2024

NCT04554056 Phase 2 COMPLETED

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Started: 9/21/2020

NCT06908928 Phase 1 RECRUITING

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Started: 8/11/2025

NCT07466160 Phase 1 RECRUITING

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Started: 2/11/2026

NCT07216560 Phase 1 RECRUITING

First-in-human Study of 7MW4911 in GI Cancer

Started: 1/13/2026

NCT07265622 Phase 1 RECRUITING

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

Started: 11/12/2025

NCT06752746 Phase 1 RECRUITING

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Started: 3/21/2024

NCT06772766 Phase 1 RECRUITING

A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

Started: 12/30/2024

NCT06079112 Phase 1 RECRUITING

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Started: 9/27/2023

NCT05773937 Phase 1 RECRUITING

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Started: 6/21/2022

NCT05803902 Phase 1 COMPLETED

An Evaluation of 9MW1911 Injection in Healthy Subjects

Started: 12/15/2021

NCT05740475 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Started: 3/20/2023

NCT06175351 Phase 1 ACTIVE NOT RECRUITING

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Started: 7/6/2023

NCT06947226 Phase 1 NOT YET RECRUITING

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Started: 4/1/2025

NCT06926998 Phase 1 NOT YET RECRUITING

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

Started: 4/15/2025

NCT06389942 Phase 1 COMPLETED

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Started: 3/10/2023

NCT05990452 Phase 1 ACTIVE NOT RECRUITING

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Started: 8/28/2023

NCT05416749 Phase 1 SUSPENDED

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Started: 8/5/2022

NCT05170243 Phase 1 COMPLETED

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Started: 1/21/2022

NCT04784312 Phase 1 COMPLETED

A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection

Started: 4/16/2021

NCT05324592 Phase 1 COMPLETED

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Started: 2/26/2021

NCT04798326 Phase 1 COMPLETED

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

Started: 6/25/2019

NCT04798313 Phase 1 COMPLETED

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

Started: 6/2/2020

NCT04533048 Phase 1 COMPLETED

A Clinical Study to Evaluate MW33 Injection

Started: 8/7/2020

Drug Candidates

bulumtatug fuvedotin 7MW3711 JS207 Cisplatin Carboplatin 7MW4911 9MW2821 Toripalimab Injection 9MW1911 Phase II placebo
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: 5/31/2024
Trials (12 months): 7
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.